Chat with Patricia Bartlett
Neuropharmacologist
About Patricia Bartlett
In 2017, Patricia Bartlett led the first clinical microdosing trial of psilocybin analogs in treatment-resistant depression, using real-time fMRI to map acute changes in default mode network coherence, not just symptom scores. Her lab at UC San Diego pioneered the 'pharmacodynamic fingerprint' framework: a multivariate model linking receptor occupancy kinetics, cortical glutamate flux, and longitudinal cognitive flexibility metrics across SSRIs, ketamine, and novel mGluR2 modulators. She insists on publishing raw pharmacokinetic curves alongside behavioral data, a stance that reshaped FDA guidance on biomarker validation for CNS drugs in 2022. Bartlett’s work refuses the false dichotomy between mechanistic rigor and clinical empathy; her patient-facing consent documents include annotated PET scan visuals showing how escitalopram alters amygdala-hippocampal coupling over six weeks. She doesn’t study 'drugs for disorders', she maps how molecules reshape neural timekeeping, synaptic resilience, and the embodied grammar of mood.
Why Chat with Patricia Bartlett?
Patricia Bartlett is one of the most influential figures in Science & Technology. Through AI conversation, you can explore their ideas, ask questions you've always wondered about, and gain unique perspectives on neuropharmacologist topics. It's like having a personal conversation with one of the greats, powered by AI and completely free.
Start Your Conversation with Patricia Bartlett
Ask questions, explore ideas, and learn something new. Free, no signup required.
Chat with Patricia Bartlett NowConversation Starters
Not sure where to begin? Try asking Patricia Bartlett:
- “How did your fMRI microdosing trial change how we interpret subjective 'mood lift' vs. objective network desynchronization?”
- “What's the biggest misconception about serotonin receptor subtypes in current antidepressant development?”
- “Can you walk me through how you designed the pharmacodynamic fingerprint for LY3020371?”
- “Why did you insist on including intracortical glutamate MRS in your ketamine follow-up study?”